Significant Presentation at EURetina 2025
AAVantgarde Bio, a leading clinical-stage biotechnology company, is poised to present updated outcomes from its LUCE-1 clinical trial at the prestigious 25th European Society of Retina Specialists (EURETINA) Annual Congress in Paris. This event, scheduled from September 4-7, 2025, offers a vital platform for advancing discussions on inherited retinal diseases.
Focus of the LUCE-1 Trial
The LUCE-1 study specifically evaluates a dual hybrid AAV-based gene therapy targeting retinitis pigmentosa, particularly in patients with Usher Syndrome type 1B, linked to mutations in the MYO7A gene. This research represents a beacon of hope for those suffering from a progressive vision loss that currently has no cure.
Key Presentation Details
The oral presentation featuring data from LUCE-1 will be delivered by Prof. Francesca Simonelli, the Principal Investigator of the trial and Head of the Ophthalmology Unit at a distinguished university hospital. This presentation will build upon previously shared findings from notable conferences, emphasizing the safety and efficacy of the therapy during its Phase 1/2 trials.
What to Expect
The session, identified as Free Paper 2, will commence at noon on September 4, 2025, where attendees can expect to learn about the latest insights and advancements in treating this devastating condition.
AAVantgarde's Commitment
AAVantgarde is driven by its mission to develop best-in-class therapies for patients suffering from inherited retinal diseases. The company’s leading candidates, AAVB-039 and AAVB-081, represent trailblazing efforts to tackle conditions like retinitis pigmentosa and Stargardt disease with no current approved treatments.
Engagement Opportunities
During the congress, AAVantgarde will be available for partnering discussions, underscoring their interest in collaboration and scientific dialogue with other professionals in the field.
About Usher Syndrome Type 1B
Usher syndrome type 1B is a significant genetic condition affecting both vision and hearing from a young age. Complications include congenital deafness and progressive vision loss, with patients often facing complete blindness as they mature. Despite existing surgical treatments for the auditory aspects of Usher syndrome, no therapeutic options are currently available for the visual decline, making gene therapies a critical area of investigation.
Company Overview
AAVantgarde Bio is at the forefront of biotech innovation, dedicated to providing solutions for patients with severe genetic disorders affecting vision. With a strong research foundation and commitment to advancing clinical excellence, the company seeks to transform treatment paradigms through robust scientific exploration.
Contact Information
For further inquiries, please reach out to Dr. Magda Blanco, Head of Corporate Development at AAVantgarde. You can email her at info@aavantgarde.com.
Frequently Asked Questions
What is the LUCE-1 trial focused on?
The LUCE-1 trial investigates a dual hybrid AAV-based gene therapy for retinitis pigmentosa related to Usher Syndrome type 1B.
Who will present the findings at EURetina 2025?
Prof. Francesca Simonelli will deliver the oral presentation on updated clinical data from the trial.
When is the presentation scheduled?
The presentation is set for September 4, 2025, at noon.
What is the mission of AAVantgarde?
AAVantgarde is dedicated to developing innovative therapies for patients with inherited retinal diseases.
How can I contact AAVantgarde for more information?
inquiries can be sent to Dr. Magda Blanco at info@aavantgarde.com.
